PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19340428-0	2009	IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.	Cyclophosphamide	166-182	immunoglobulin heavy variable 3-69-1 (pseudogene)	Homo sapiens	0-4	
19340428-0	2009	IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.	Cyclophosphamide	166-182	lipoprotein lipase	Homo sapiens	32-35	
19340428-10	2009	Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies.	fludarabine	163-174	lipoprotein lipase	Homo sapiens	31-34	
19340428-10	2009	Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies.	fludarabine	163-174	ADAM metallopeptidase domain 29	Homo sapiens	39-45	
19340428-10	2009	Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies.	fludarabine	163-174	immunoglobulin heavy variable 3-69-1 (pseudogene)	Homo sapiens	76-80	
19340428-10	2009	Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies.	Cyclophosphamide	177-193	lipoprotein lipase	Homo sapiens	31-34	
19340428-10	2009	Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies.	Cyclophosphamide	177-193	ADAM metallopeptidase domain 29	Homo sapiens	39-45	
19340428-10	2009	Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies.	Cyclophosphamide	177-193	immunoglobulin heavy variable 3-69-1 (pseudogene)	Homo sapiens	76-80